Antibody Information
General Information of This Antibody
| Antibody ID | ANTI0OWAGG |
|||||
|---|---|---|---|---|---|---|
| Antibody Name | 008 (BCMA) |
|||||
| Organization | CSPC MEGALITH BIOPHARMACEUTICAL CO.,LTD. |
|||||
| Synonyms |
008 (BCMA)
Click to Show/Hide
|
|||||
| Antibody Type | Monoclonal antibody (mAb) |
|||||
| Antibody Subtype | Humanized lgG |
|||||
| Antigen Name | Tumor necrosis factor receptor superfamily member 17 (TNFRSF17) |
Antigen Info | ||||
| Click to Show/Hide the Sequence Information of This Antibody | ||||||
| Heavy Chain Sequence |
QVQLVQSGAEVKKPGSSVKVSCKASGGTFSNYWMHWVRQAPGQGLEWMGATYRGHSDTYY
NQKFKGRVTITADKSTSTAYMELSSLRSEDTAVYYCARGAIYDGYDVLDNWGQGTLVTVS SASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLOS SGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLG GPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQY NSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRD ELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSR WQQGNVFSCSVMHEALHNHYTQKSLSLSPGK Click to Show/Hide
|
|||||
| Heavy Chain CDR 1 |
NYWMH
Click to Show/Hide
|
|||||
| Heavy Chain CDR 2 |
ATYRGHSDTYYNQKFKG
Click to Show/Hide
|
|||||
| Heavy Chain CDR 3 |
GAIYDGYDVLDN
Click to Show/Hide
|
|||||
| Light Chain Sequence |
DIQMTQSPSSLSASVGDRVTITCSASQDISNYLNWYQQKPGKAPKLLIYYTSNLHSGVPS
RFSGSGSGTDFTLTISSLQPEDFATYYCQQYRKLPWTFGQGTKLEIKRTVAAPSVFIFPP SDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLT LSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC Click to Show/Hide
|
|||||
| Light Chain CDR 1 |
SASQDISNYLN
Click to Show/Hide
|
|||||
| Light Chain CDR 2 |
YTSNLHS
Click to Show/Hide
|
|||||
| Light Chain CDR 3 |
QQYRKLPWT
Click to Show/Hide
|
|||||
Each Antibody-drug Conjugate Related to This Antibody
Full Information of The Activity Data of The ADC(s) Related to This Antibody
wO2024222841A1 ADC62 [Investigative]
Revealed Based on the Cell Line Data
| Experiment 1 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Half Maximal inhibitory Concentration (lC50) |
0.12 nM
|
High BCMA expression (BCMA+++) | ||
| Method Description |
Cytotoxicity of ADC to NCI-H929 cells
|
||||
| In Vitro Model | Plasma cell myeloma | NCI-H929 cells | CVCL_1600 | ||
wO2024222841A1 ADC64 [Investigative]
Revealed Based on the Cell Line Data
| Experiment 1 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Half Maximal inhibitory Concentration (lC50) |
0.14 nM
|
High BCMA expression (BCMA+++) | ||
| Method Description |
Cytotoxicity of ADC to NCI-H929 cells
|
||||
| In Vitro Model | Plasma cell myeloma | NCI-H929 cells | CVCL_1600 | ||
wO2024222841A1 ADC62-4 [Investigative]
Revealed Based on the Cell Line Data
| Experiment 1 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Half Maximal inhibitory Concentration (lC50) |
0.21 nM
|
High BCMA expression (BCMA+++) | ||
| Method Description |
Cytotoxicity of ADC to NCI-H929 cells
|
||||
| In Vitro Model | Plasma cell myeloma | NCI-H929 cells | CVCL_1600 | ||
wO2024222841A1 ADC64-4 [Investigative]
Revealed Based on the Cell Line Data
| Experiment 1 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Half Maximal inhibitory Concentration (lC50) |
0.29 nM
|
High BCMA expression (BCMA+++) | ||
| Method Description |
Cytotoxicity of ADC to NCI-H929 cells
|
||||
| In Vitro Model | Plasma cell myeloma | NCI-H929 cells | CVCL_1600 | ||